valu usd unless otherwis note
macro angst high-qual rais
beat rais upsid organ growth led life scienc
diagnost solid result reinforc portfolio today
mostli lever defens life scienc sector rather
industri short-cycl demand choppier late ge
biopharma acquisit dental ipo progress track
expect complet
high-qual beat rais led diagnost life scienc
danah cash ep nice outpac consensu
driven robust organ growth across life scienc
complet differ cycl vs industri short-cycl demand macro
pressur expect dictat choppi earn season
nitpick soon-to-be-ipo dental slip back
organ revenu declin due now-familiar headwind tradit
consum equip expect boost
organ revenu growth guidanc follow robust
achiev full-year cash ep guidanc rang boost
low-end manag attribut beat
high-end maintain due increment fx tariff
headwind reaffirm cash ep estim
rais price target
biggest surpris drama-fre oper result even industri
vertic though industrial-ori end market account
sale note order busi remain steadi
contrast recent soften industri datapoint like
ism would consid strong read broader
industri demand drama-fre result underscor defens high-
qualiti natur even market expos industri cycl
comp due tougher y/i comp water qualiti organ growth
deceler still-healthi mid-single-digit trojan
double-digit thank strength municip industri hach
low-single-digit double-digit comp continu
believ pursu separ water qualiti
dental ipo deal complet danah plan host
qualiti analyst meet sept fit mosaic
compani could consid divestitur busi new
public compani either stand-alone pair product id
valuat high-end rel rang trade
premium peer adjust ep vs target rang
price target assum trade premium
price prior trade day market close estimate unless otherwis note
best-in-class multi-industri name metric
hold much-covet posit among higher
qualiti prime coverag accord
sector-best consecut year
know-how rever danah busi system
posit includ recur revenu market
leadership across portfolio
acquir biopharma busi bil
announc acquir biopharma
busi bil impli reason deal multipl
ev/ebitda deal expect produc mil
cost save roughli
cash ep accret ge biopharma lead provid
instrument consum softwar support
research discoveri process develop manufactur
workflow biopharmaceut drug
separ dental independ compani
ipo stage exit conjunct
deal announc manag reveal
switch structur dental divestitur
spin-out ipo stage exit would gener
up-front cash proce help de-lev danah balanc
sheet manag expect offer stake
ipo retain flexibl execut stage exit
remain ownership futur primari rational
separ dental view flexibl
organ invest stand-alone compani
recal argument behind danah
success spin-off
given expens price-tag below-benchmark
expect return major integr stumbl ge
biopharma pall cepheid would damag faith
investor disciplin also
enhanc scrutini dental segment turnaround given
process spun independ
publicli trade compani
bloomberg capit market estim upside/downside/target
given portfolio migrat toward higher-tech life scienc
busi believ re-rat higher
toward target rel price-to-earnings premium rang
believ trade high-end
rang due solid outlook investor
enthusiasm pend dental ipo biopharma
acquisit premium target group
multipl price-to-earnings adjust ep
cash ep impli valuat support
market enter risk-off environ danah
deliv upsid synergies/accret target
stronger dental perform believ stock
may abl re-rat beyond high-end rel
rang premium target group multipl
adjust ep also see potenti
upsid adjust ep reach level includ
acceler organ growth end market improv
carri execut risk misstep
 integr dental turnaround could weigh
stock addit high-qual defens name
would lag market enter prolong risk-on
environ favor cyclic higher-beta stock could
see price-to-earnings contract premium peer
midpoint target rel rang also
risk end market slowdown result adjust
ep closer valuat
takeaway result
revenu high growth
market high-
single-digit quarter
led double-digit
india china
develop market like
us western europ
mid-single-digit
cash ep outpac consensu mostli driven oper line
report cash ep beat estim consensu
high-end guidanc third quarter row organ revenu
growth held steadi outpac estim driven robust across
life scienc diagnost said nitpick result
soon-to-be-ipo dental slip back organ revenu declin though
tougher y/i comp adjust oper margin expand bp y/i
slightli surpass estim increment margin respect
quarter overal oper line beat estim compris life scienc
diagnost dental environment appli solut
line higher interest incom mandatori convert prefer stock mcp proce
ad ep upsid lower tax rate ad final free cash flow convers
adjust net incom quarter robust touch danah
histor averag convers
capit market compani report note organ revenu growth estim sector actual
rais low-end cash ep guidanc boost organ growth target
expect boost low-end cash ep guidanc rang
move midpoint new
midpoint essenti in-lin consensu time releas accord
compani boost low-end attribut solid beat
unchang high-end due increment fx tariff headwind anticip
importantli recal manag declin updat organ growth guidanc
earn want wait better visibl trend
achiev organ growth compani final enough convict
boost full-year forecast previous maintain cash
ep estim still high-end guidanc
initi cash ep guidanc fell slightli short consensu
concern notion lighter guidanc rang attribut
compani bia under-promis importantli highlight
organ growth forecast roughli touch better prior estim
addit compani target oper margin roughli
includ higher fx tariff headwind trim cash ep
estim high-end guidanc
organ growthshad area multi-industri sector averagenot restatedfor spin electr equip multi-industri
exhibit danah earn guidanc vs estim consensu
life scienc sale life scienc achiev organ revenu growth
repres segment fifth consecut quarter high-single-digit growth oper
margin bp y/i thank impress dbs-driven execut across segment
beckman life scienc high-single-digit sciex mid-single-digit pall
achiev high-single-digit organ growth quarter pall industri mid-single-
digit strong result aerospac process industri partli off-set weak
microelectron meanwhil pall life scienc double-digit led biotech
busi final offici reach one-year anniversari sinc acquisit apr-
deliv anoth quarter double-digit organ growth
diagnost diagnost organ revenu highest growth
sinc thank organ growth cepheid due dbs-driven momentum
north america high growth market radiomet high-single-digit
beckman diagnost leica biosystem mid-single-digit includ market share
gain said oper margin segment bp y/i
manag attribut impact fx headwind tariff-rel cost
dental ahead upcom ipo mid- dental disappointingli slip
back organ revenu declin low-single-digit growth
specialti consum busi off-set low-single-digit declin perenni
challeng tradit consum equip busi geograph china
million annual revenu segment achiev third consecut quarter double-
digit growth off-set continu soft western europ latin
america result weaker volum fx headwind increas invest new
product develop segment oper margin contract bp y/i
look ahead manag expect dental organ revenu roughli flat y/i
prior forecast low-single-digit growth said ipo dental
name envista led future-ceo amir aghdaei current serv group
execut dental still track complet
deceler slightli compris low-single-digit product id mid-single-
digit qualiti segment face tougher y/i comp product id videojet
low-single-digit growth high-single-digit prior year comp though underli
organ growth thank strength municip industri end market chemtreat
deliv high-single-digit organ growth thank strength food beverag commerci
oil ga vertic final hach organ revenu growth deceler low-single-digit
vs double-digit prior year comp though perform north america western europ
remain solid manag spotlight upcom analyst meet septemb
hach headquart loveland colorado detail qualiti
platform share
detail ge
pleas see
report
plan rais debt
financ ge
biopharma deal closer
expect complet
date lower
benefit debt
upcom catalyst point monitor
acquir billion reason ev/ebitda multipl feb-
announc acquir ge life scienc biopharma busi cash
purchas price billion includ billion anticip tax benefit net
purchas price roughli billion impli reason deal multipl
price/sal ev/ebitda surpris announc
alway view natur buyer life scienc busi given
complementari natur portfolio recent aggress push expand
biopharma life scienc offer ge biopharma manag
purchas price fund mixtur cash hand new debt issuanc
billion equiti offer complet compani expect credit rate
downgrad still-invest grade bbb follow deal addit
deal expect produc million annual cost save year-thre along
potenti futur revenu synergi though manag yet size opportun
regard accret estim deal gener cash
ep doubl year-fiv total expect achiev
high-single-digit year-fiv consist typic return threshold larg
acquisit deal still track close
ge biopharma lead player bioprocess workflow grow organ
ge biopharma lead provid instrument consum softwar
support research discoveri process develop manufactur workflow
biopharmaceut drug busi expect gener annual revenu
billion ebitda margin equat billion annual ebitda
annual free cash flow also roughli billion addit revenu mix roughli
consum equip manag expect achiev
organ revenu growth thank secular driver across biolog drug develop cell
gene therapi demand high growth market key product line within
busi includ downstream bioprocess revenu mix upstream
bioprocess
separ dental independ compani ipo stage exit
conjunct ge biopharma deal announc manag reveal
switch structur dental divestitur spin-out ipo
stage exit would gener up-front cash proce help de-lev danah balanc
sheet follow acquisit manag expect offer roughli
stake ipo retain flexibl execut stage exit remain ownership
futur either spinout secondari offer time-frame ipo still
mid- manag primari rational separ dental view
flexibl organ inorgan invest includ
stand-alone compani recal argument led compani spin-off
industri busi current group execut presid
dental amir aghdaei becom presid ceo spinco former danah cfo
coma serv special advisor new compani name
corpor ticker new york stock exchang
believ could eventu separ qualiti platform
stand-alone entiti follow complet ge biopharma acquisit ipo
dental believ could begin orchestr separ best-in-class
qualiti platform either stand-alone busi pair product id
billion revenu mix water qualiti market leader water
believ plan
host upcom
analyst meet
water qualiti fit
mosaic could
consid plan
separ busi
test/analyt hach brand ultraviolet disinfect trojan
technolog brand chemic disinfect chemtreat brand among
leader membran filtrat pall brand busi sit squar
high-end water technolog continuum command higher valuat
barrier entri margin growth water qualiti total address market
billion size grow low- mid-single-digit busi plan outpac
market use share gain new product develop expans high growth market
given high demand water pure-play asset today believ spin ipo
qualiti stand-alone public entiti would tremend appeal investor similarli
anticip larg water player like suez would saliv opportun
rel price-to-earnings trade high-end rel rang share
current trade premium multi-industri sector report ep
cash ep believ stock trade premium target
group multipl high-end histor rel rang impli
price target support sector perform rate
ev/ebitda premium ev/ebitda basi trade
estim repres rel premium multi-industri peer group averag
surpris premium group given outsiz a-driven
amort premium price-to-earnings
share price trade premium weight averag price-to-earnings
publicly-trad peer report ep cash ep believ
deserv premium reflect market leadership db toolkit
price assum after-tax cost capit beta annual sale growth
termin growth rate
compani report capit market estim
millionsmarjunsepdecmar-ajun-asepdecmarjunsepdecmarjunsepdecseg revenueslif environment appli total revenu organ revenu sale gener incomelif appli expens oper interest expens incom intang per share per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax new pension account corpor expens exhibit danah annual incom statement
compani report capit market estim
revenueslif appli revenu sale gener incomelif appli expens oper income/expense- net interest intang per share earn per share earn per share outstand outstand analysi gross oper pre-tax net incom sale sell gener research tax asdiscontinu oper electr equip multi-industri
given portfolio migrat toward higher-tech life scienc busi believ
re-rat higher toward target rel price-to-earnings premium rang
believ trade high-end rang due solid
outlook investor enthusiasm pend dental ipo biopharma acquisit
premium target group multipl price-to-earnings adjust
ep cash ep impli valuat support sector perform rate
risk rate price target
acquisit one acquisit compani sector alway risk
overpay experienc integr difficulti major deal believ
integr stumbl would damag investor trust leadership
organ growth acquisition-focus busi model investor often hone
organ revenu growth metric perceiv miss often
disproportion effect stock earn
econom condit macro trend inflat currenc credit avail suppli
chain materi cost could caus result lower forecast
financi risk disrupt global credit market could caus sale
earn estim optimist
margin sinc gener among highest gross margin sector
degre execut risk would see shortfal profit
regulatori chang govern regul us intern could
neg impact compani especi elev
beneficiari increas regul water product mark
manag success oper histori execut legendari
db framework seen manag talent period poach
industri compani time exodu talent could affect oper
manufactur market profession medic industri commerci
product servic facil locat across countri compani oper
four segment life scienc diagnost dental environment appli solut
also oper differenti framework growth lean leadership tool
process known danah busi system across aspect oper includ
product develop qualiti control global sourc sale market danah
modestli headquart washington employ peopl global
